For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Attruby represents a true change. These novel therapies preserve the transthyretin protein, halting its destructive build-up and alleviating the severity of the disease . People are now reporting benefits in their quality of